INT158083

Context Info Confidence 0.67 First Reported 2006 Last Reported 2010 Negated 0 Speculated 1 Reported most in Body Documents 24 Total Number 25 Disease Relevance 6.82 Pain Relevance 2.83

cytosol (FGD1) signal transduction (FGD1) Golgi apparatus (FGD1) plasma membrane (FGD1) cytoskeleton (FGD1) nucleus (FGD1)

Anatomy Link Frequency fat 1 urine 1 FGD1 (Homo sapiens)

Pain Link Frequency Relevance Heat cva 31 100.00 Pain 149 99.00 addiction 271 95.00 alcohol 175 94.88 depression 225 93.12 aspirin 11 92.36 Potency 33 90.52 anesthesia 17 88.64 rheumatoid arthritis 18 77.00 cINOD 20 76.68

Disease Link Frequency Relevance Heat Pulmonary Embolism 25 100.00 Acute Coronary Syndrome 24 100.00 Syndrome 21 100.00 Renal Disease 72 99.86 Pain 146 99.00 Malaria 11 98.08 Alopecia 44 95.96 Aggression 169 94.28 Hypesthesia 37 93.28 Depression 268 93.12

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

AAS are found in both cities and smaller communities [3].

Gene_expression (found) of AAS

1) Confidence 0.67 Published 2008 Journal Subst Abuse Treat Prev Policy Section Body Doc Link PMC2612649 Disease Relevance 0.11 Pain Relevance 0.08

The development of late combined drug use starting with AAS

Gene_expression (with) of AAS

2) Confidence 0.66 Published 2008 Journal Subst Abuse Treat Prev Policy Section Body Doc Link PMC2612649 Disease Relevance 0.32 Pain Relevance 0.38

One important finding was that most AAS users generally expressed a positive view about the effects of AAS.

Gene_expression (expressed) of AAS

3) Confidence 0.58 Published 2008 Journal Subst Abuse Treat Prev Policy Section Body Doc Link PMC2612649 Disease Relevance 0.06 Pain Relevance 0

The development of oscillating drugs of abuse and AAS use

Gene_expression (use) of AAS

4) Confidence 0.58 Published 2008 Journal Subst Abuse Treat Prev Policy Section Body Doc Link PMC2612649 Disease Relevance 0.13 Pain Relevance 0.08

By the age of 25, after five years of AAS abuse, he was tested for AAS use at the gym at which he trained.

Gene_expression (use) of AAS

5) Confidence 0.58 Published 2008 Journal Subst Abuse Treat Prev Policy Section Body Doc Link PMC2612649 Disease Relevance 0.41 Pain Relevance 0.25

Altogether, John was taking fourteen human and veterinary AAS products during a period of five years (oral: oxymetholone, stanozolol, methandrostenolone and methenolone acetate; injected: trenbolone acetate, testosterone blends, boldenone, nandrolone esters, methenolone and stanozolol).

Gene_expression (products) of AAS

6) Confidence 0.58 Published 2008 Journal Subst Abuse Treat Prev Policy Section Body Doc Link PMC2612649 Disease Relevance 0.15 Pain Relevance 0.09

An important finding in this study is that most of the patients describe their early experiences of AAS as definitely positive, perhaps even as the best time of their lives.

Gene_expression (experiences) of AAS

7) Confidence 0.58 Published 2008 Journal Subst Abuse Treat Prev Policy Section Body Doc Link PMC2612649 Disease Relevance 1.00 Pain Relevance 0.11

Early on in her AAS use, she also used ephedrine and other preparations to reduce subcutaneous fat and fluid in the muscles (e.g. bronchodilators and a drug which contained a combination of ephedrine, caffeine and aspirin).

Gene_expression (use) of AAS in fat associated with aspirin

8) Confidence 0.58 Published 2008 Journal Subst Abuse Treat Prev Policy Section Body Doc Link PMC2612649 Disease Relevance 0.24 Pain Relevance 0.18

In the six years during which she used hormones, she used four different types of AAS (oral: methandrostenolone and stanozolol; injected: methenolone enanthate and stanozolol).

Gene_expression (types) of AAS

9) Confidence 0.58 Published 2008 Journal Subst Abuse Treat Prev Policy Section Body Doc Link PMC2612649 Disease Relevance 0.24 Pain Relevance 0.15

The first AAS he bought was a testosterone product that was to be injected into the buttock.

Gene_expression (product) of AAS

10) Confidence 0.58 Published 2008 Journal Subst Abuse Treat Prev Policy Section Body Doc Link PMC2612649 Disease Relevance 0.08 Pain Relevance 0.06

One important finding was that most AAS users generally expressed a positive view about the effects of AAS.

Gene_expression (expressed) of AAS

11) Confidence 0.58 Published 2008 Journal Subst Abuse Treat Prev Policy Section Body Doc Link PMC2612649 Disease Relevance 0.11 Pain Relevance 0

The presence of AAS, which may indicate an early phase of allodynia, did not influence the efficacy of almotriptan therapy.

Gene_expression (presence) of AAS

12) Confidence 0.30 Published 2009 Journal Headache Section Body Doc Link 19220503 Disease Relevance 0 Pain Relevance 0

"We usually do not pay for palpation, measuring blood pressure and weight, but do pay 200 shillings for laboratory test for urine, malaria, amount of blood, and ANC cards and this applies to government and private health facilities" (FGD participants, Kitomondo village, Mkuranga)

Gene_expression (participants) of FGD in urine associated with malaria

13) Confidence 0.12 Published 2010 Journal Malar J Section Body Doc Link PMC2837674 Disease Relevance 0.17 Pain Relevance 0

INTERVENTION: PCS or AAS using PR.

Gene_expression (using) of AAS

14) Confidence 0.10 Published 2010 Journal Gastrointest. Endosc. Section Body Doc Link 20493481 Disease Relevance 0.33 Pain Relevance 0

Each FGD comprised eight participants (only one FGD had seven people) and lasted for almost two hours.

Gene_expression (comprised) of FGD

15) Confidence 0.10 Published 2010 Journal Journal of Health, Population, and Nutrition Section Body Doc Link PMC2975851 Disease Relevance 0 Pain Relevance 0

Each FGD comprised eight participants (only one FGD had seven people) and lasted for almost two hours.

Gene_expression (comprised) of FGD

16) Confidence 0.10 Published 2010 Journal Journal of Health, Population, and Nutrition Section Body Doc Link PMC2975851 Disease Relevance 0 Pain Relevance 0

In addition to affording AAS induced renal impairment investigations, animal models will facilitate controlled comparative pharmacokinetic studies of short and long term AAS exposure in mice.

Gene_expression (exposure) of AAS

17) Confidence 0.09 Published 2010 Journal Subst Abuse Treat Prev Policy Section Body Doc Link PMC2877023 Disease Relevance 0.15 Pain Relevance 0

UGTs not only contribute to AAS glucuronidation but they also act as conjugating enzymes for various other pharmaceutical drugs [35,43].

Gene_expression (glucuronidation) of AAS

18) Confidence 0.09 Published 2010 Journal Subst Abuse Treat Prev Policy Section Body Doc Link PMC2877023 Disease Relevance 0.06 Pain Relevance 0.15

More research on AAS metabolism in the presence of UGT2B17 gene deletion is required.

Gene_expression (metabolism) of AAS

19) Confidence 0.09 Published 2010 Journal Subst Abuse Treat Prev Policy Section Abstract Doc Link PMC2877023 Disease Relevance 0.28 Pain Relevance 0

The occurrence of renal disorders among AAS users

Gene_expression (users) of AAS associated with renal disease

20) Confidence 0.09 Published 2010 Journal Subst Abuse Treat Prev Policy Section Body Doc Link PMC2877023 Disease Relevance 0.75 Pain Relevance 0.38

General Comments

This test has worked.